You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!
NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
St. Helier, Jersey
52 Week High
52 Week Low
The Motley FoolMay 7
5 Key Takeaways From NovoCure's Big First-Quarter
Novocure (NASDAQ:NVCR), a fast-growing medical device company focused on cancer, reported its first-quarter results on May 2. NovoCure's stock has been red-hot over the last few years as it works to bring its innovative product -- a device called Optune that makes use of a new therapy called tumor treating fields -- to more patients who suffer from a deadly form of brain cancer called glioblastoma multiforme (GBM). Novocure's stock rose more than 8% on the day following the earnings announcement. What was...
Seeking AlphaMay 2
NovoCure Limited 2019 Q1 - Results - Earnings Call Slides
The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q1 earnings call. 1 14 Click to enlarge Notes:...
Yahoo FinanceMay 2
NovoCure: 1Q Earnings Snapshot
SAINT HELIER, Jersey (AP) _ NovoCure Ltd. (NVCR) on Thursday reported a loss of $12.2 million in its first quarter. The Saint Helier, Jersey-based company said it had a loss of 13 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 13 cents per share. The oncology drug developer posted revenue of $73.3 million in the period, falling short of Street forecasts. Three analysts surveyed by Zacks expected...
Expected Jul 25, Pre-Market